Daniela Rezek
Overview
Explore the profile of Daniela Rezek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schilling J, Kurbacher C, Hanusch C, Busch S, Hollander M, Kreiss-Sender J, et al.
Breast Care (Basel)
. 2022 Jun;
17(2):130-136.
PMID: 35702496
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of...
2.
Kummel A, Kummel S, Blohmer J, Faridi A, Nitz U, Loibl S, et al.
Breast Care (Basel)
. 2019 Jul;
14(3):165-169.
PMID: 31316315
Background: Autologous fat transfer in breast reconstruction has become increasingly important in breast reconstructive surgery. Although the indication to obtain fat, the various operative procedures, and the risks for the...
3.
Wallwiener M, Nabieva N, Feisst M, Fehm T, de Waal J, Rezai M, et al.
BMC Cancer
. 2019 Jun;
19(1):611.
PMID: 31227025
Background: Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative...
4.
Rhiem K, Bucker-Nott H, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, et al.
Breast J
. 2019 Apr;
25(3):455-460.
PMID: 30953388
The detection of deleterious germline mutations in BRCA1 and BRCA2 considerably influences the clinical management of healthy and diseased carriers. Therefore, the identification of persons at risk who could uptake...
5.
Dall P, Koch T, Gohler T, Selbach J, Ammon A, Eggert J, et al.
BMC Cancer
. 2018 Jan;
18(1):51.
PMID: 29310623
Background: The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence...
6.
Dall P, Koch T, Gohler T, Selbach J, Ammon A, Eggert J, et al.
Oncologist
. 2017 Feb;
22(2):131-138.
PMID: 28174294
Purpose: Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study,...
7.
Gass P, Fasching P, Fehm T, de Waal J, Rezai M, Baier B, et al.
Breast Care (Basel)
. 2016 Dec;
11(5):315-322.
PMID: 27920623
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy...
8.
Hack C, Fasching P, Fehm T, de Waal J, Rezai M, Baier B, et al.
Integr Cancer Ther
. 2016 Sep;
16(2):165-175.
PMID: 27627986
Background: Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study...